We comprehensively validated the targeting of CePA on mTOR at the in vivo, ex vivo, and bioinformatic levels, which provides a theoretical basis for the prevention and treatment of MASH. Here, MTOR is linked to metabolic dysfunction-associated steatohepatitis.